NCT05186493 Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers
| NCT ID | NCT05186493 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Locally Advanced Pelvic Cancer That Require Pelvic Exenteration |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2021-11-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Radium Hospital Oslo University Hospital Estimated date of first patient enrolled: 3rd quarter 2021 Anticipated recruitment period: 4 years Estimated date of last patient completed: 4th quarter 2025 Locally advanced pelvic cancer that requires total pelvic exenteration Expected study-specific follow-up period per patient: 5 years according to standard follow-up for this patient group Primary endpoint: R0 resection rate (circumferential resection margin \>1mm) Secondary endpoints: Rate of conversion to open surgery, peri- and postoperative complications, hospital length of stay, wound healing at 3 months follow-up, Quality of Life measured by EORTC Quality of Life Questionnaire C-30 preoperatively, at 3 months and 3 year follow-ups, disease-free survival, overall survival. Diagnosis specific endpoints. Open label observational study.
Eligibility Criteria
Inclusion Criteria: * Adult patients (\>18 years) * locally advanced pelvic cancer that require pelvic exenteration * eligible for robot- assisted minimally invasive surgery by the respective multidisciplinary teams, may be included in the study. Exclusion Criteria: * Any reason why the patient in the investigator's opinion is not suited for inclusion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05186493 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Pelvic Cancer That Require Pelvic Exenteration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05186493 currently recruiting?
Yes, NCT05186493 is actively recruiting participants. Contact the research team at ebbtho@rr-research.no for enrollment information.
Where is the NCT05186493 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT05186493 clinical trial?
NCT05186493 is sponsored by Oslo University Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.